Abrégé

The present disclosure relates to targeting moieties such as peptides that can bind to B7-H3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and/or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

Classes IPC  ?

• C07K 7/64 - Peptides cycliques ne comportant que des liaisons peptidiques normales
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 51/08 - Peptides, p. ex. protéines

Abrégé

The present disclosure relates to processes for preparing peptides that can bind to DLL3.

Classes IPC  ?

• C07K 7/64 - Peptides cycliques ne comportant que des liaisons peptidiques normales
• C07K 1/06 - Procédés généraux de préparation de peptides utilisant des groupes protecteurs ou des agents d'activation

Abrégé

The present disclosure relates to enriched and stable radiopharmaceutical compositions comprising [225Ac]Ac-DOTA-TATE.

Classes IPC  ?

• A61K 51/08 - Peptides, p. ex. protéines
• A61K 51/10 - Anticorps ou immunoglobulinesLeurs fragments
• A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
• A61K 103/40 - Actinides
• A61P 35/00 - Agents anticancéreux

Abrégé

The present disclosure relates to targeting moieties such as peptides that can bind to B7-H3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and/or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

Classes IPC  ?

• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
• A61P 35/00 - Agents anticancéreux
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides

Abrégé

The present disclosure relates to stable compositions comprising a radiolabeled compound, and related pharmaceutical compositions and methods of manufacture. Such compositions are useful in both the diagnostic imaging of and the treatment of diseases (e.g., cancer).

Classes IPC  ?

• A61K 51/08 - Peptides, p. ex. protéines
• A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61P 35/00 - Agents anticancéreux

Abrégé

The present disclosure relates to targeting moieties such as peptides that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and/or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

Classes IPC  ?

• A61K 38/12 - Peptides cycliques
• C07K 11/02 - Depsipeptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés cycliques, p. ex. valinomycines

Abrégé

The present disclosure relates to stable compositions comprising a radiolabeled compound, and related pharmaceutical compositions and methods of manufacture. Such compositions are useful in both the diagnostic imaging of and the treatment of diseases (e.g., cancer).

Classes IPC  ?

• A61K 51/08 - Peptides, p. ex. protéines
• A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
• A61P 35/00 - Agents anticancéreux
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• A61K 103/30 - Terres rares
• A61K 103/40 - Actinides

Abrégé

The present disclosure relates to targeting moieties such as peptides that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and/or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• A61P 35/00 - Agents anticancéreux
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 51/08 - Peptides, p. ex. protéines

Abrégé

The present disclosure relates to targeting moieties such as peptides that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and/or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

Classes IPC  ?

• A61K 51/04 - Composés organiques
• A61K 51/08 - Peptides, p. ex. protéines
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés

Abrégé

The present disclosure relates to targeting moieties such as peptides and antibodies that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and/or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

Classes IPC  ?

• C07K 7/50 - Peptides cycliques contenant au moins une liaison peptidique anormale
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 51/08 - Peptides, p. ex. protéines

Abrégé

The present disclosure relates to targeting moieties such as peptides and antibodies that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and/or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

Classes IPC  ?

• C07K 7/64 - Peptides cycliques ne comportant que des liaisons peptidiques normales
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

The present disclosure relates to targeting moieties such as peptides and antibodies that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and/or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

Classes IPC  ?

• A61P 35/00 - Agents anticancéreux
• A61K 51/08 - Peptides, p. ex. protéines
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

The present disclosure relates to targeting moieties such as peptides and antibodies that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and/or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

Classes IPC  ?

• A61P 35/00 - Agents anticancéreux
• A61K 51/08 - Peptides, p. ex. protéines
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

The present disclosure relates to targeting moieties such as peptides that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and/or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

Classes IPC  ?

• A61P 35/00 - Agents anticancéreux
• A61K 51/08 - Peptides, p. ex. protéines
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 38/00 - Préparations médicinales contenant des peptides

Produits et services

pharmaceutical research and development services in the field of oncology